Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 196-203

  Fitzsimmons, Patrick J ^a   Forough, Reza ^a   Lawrence, Mark E ^a   Gantt, D Scott ^a   Rajab, M Hasan ^b   Kim, Hyunsun ^b   Weylie, Brian ^a   Spiekerman, A Michael ^b   Dehmer, Gregory J ^a  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Atherosclerosis; Coronary artery disease; Inflammation; Matrix metalloproteinases

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIURETIC AGENT; ENOXAPARIN; GELATINASE A; GELATINASE B; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; TISSUE INHIBITOR OF METALLOPROTEINASE;

ACUTE CORONARY SYNDROME; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; URINALYSIS; URINE LEVEL;

ACUTE DISEASE; AGED; BIOLOGICAL MARKERS; CHEMISTRY, CLINICAL; CORONARY ARTERY DISEASE; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; REFERENCE VALUES; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 34648860543     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.027     Document Type: Article

References (34)

1. Lijnen H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 86 (2001) 324-333
2. Kaartinen M., Penttilä A., and Kovanen P.T. Accumulation of activated mast cells in the shoulder region of human coronary atheroma, the predilection site of atheromatous rupture. Circulation 90 (1994) 1669-1678
3. Inocubo Y., Hanada H., Ishizaka H., et al. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 (2001) 211-217
4. Kai H., Ikeda H., Yasukawa H., et al. Peripheral blood levels of matrix metalloproteineases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 32 (1998) 368-372
5. Ohtsuka T., Hamada M., Saeki H., et al. Serum levels of matrix metalloproteinases and tumor necrosis factor-α in patients with idiopathic dilated cardiomyopathy and effect of carvediolol on these levels. Am J Cardiol 91 (2003) 1024-1027
6. Polyakova V, Hein S, Kostin S, et al. Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 2004;44:1609-18.
7. Cedro K., Radomski A., Radomski M.W., et al. Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study. Int J Cardiol 92 (2003) 185-188
8. Miyamoto S., Nagaya N., Ikemoto M., et al. Elevation of matrix metalloproteinase-2 level in pericardial fluid is closely associated with left ventricular remodeling. Am J Cardiol 89 (2002) 102-105
9. Thrailkill K.M., Kumar S., Rosenberg C.K., et al. Characterization of matrix metalloproteinases in human urine: alterations during adolescence. Pediatr Nephrol 13 (1999) 223-229
10. Gerhards S., Jung K., Koenig F., et al. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with high stage and grade of bladder carcinoma. Urology 57 (2001) 675-679
11. Benisty J.I., Folkman J., Zurakowski D., et al. Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest 128 (2005) 572S
12. Pai J.K., Pischon T., Ma J., et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351 (2004) 2599-2610
13. Ambrose J.A., Winters S.L., Stern A., et al. Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 5 (1985) 609-616
14. Freeman M.R., Williams A.E., Chisholm R.J., et al. Intracoronary thrombus and complex morphology in unstable angina. Relation to timing of angiography and in-hospital cardiac events. Circulation 80 (1989) 17-23
15. Sadatmansoori S., MacDougall J., Khademi S., et al. Construction, expression, and characterization of a baculovirally expressed catalytic domain of human matrix metalloproteinase-9. Protein Expr Purif 23 (2001) 447-452
16. Forough R., Koyama N., Hasenstab D., et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 79 (1996) 812-820
17. Allaire E., Forough R., Clowes M., et al. Local overexpression of TIMP-1 prevents aortic aneurysm degeneration and rupture in a rat model. J Clin Invest 102 (1998) 1413-1420
18. Snedecor G.W., and Cochran W. Statistical methods. 7th ed. (1980), The Iowa State University Press, Ames, IA p. 135-48
19. Tayebjee M.H., Lip G.Y.H., Tan K.T., et al. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96 (2005) 339-345
20. Kato R., Momiyama Y., Ohmori R., et al. Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex plaques. Am J Cardiol 95 (2005) 90-92
21. Inoue T., Kato T., Takayanagi K., et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol 92 (2003) 1461-1464
22. Manginas A., Bei E., Chaidaroglou A., et al. Peripheral levels of matrix metalloproteinase-9, interleukin-6 and C-Reactive protein are elevated in patients with acute coronary syndromes: correlations with serum troponin I. Clin Cardiol 28 (2005) 182-186
23. Eckart R.E., Uyehara C.F., Shry E.A., et al. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Inter Cardiol 17 (2004) 27-31
24. Hojo Y., Ikeda U., Katsuki T., et al. Matrix metalloproteinase expression in the coronary circulation induced by coronary angioplasty. Atherosclerosis 161 (2002) 185-192
25. Biasucci L.M., Liuzzo G., Fantuzzi G., et al. Increased levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 99 (1999) 2079-2084
26. Blankenberg S., Rupprecht H.J., Poirier O., et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107 (2003) 1579-1585
27. Zouridakis E., Avanzas P., Arroyo-Espliguero R., et al. Markers of inflammation and rapid coronary artery disease progression in patients with stable angina pectoris. Circulation 110 (2004) 1747-1753
28. Alverez B., Ruiz C., Chacon P., et al. Serum values of metalloproteinase-2 and metalloproteinoase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 40 (2004) 469-475
29. LeMaire S.A., Wang X., Wilks J.A., et al. Matrix metalloproteinases in ascending aortic aneurysms: bicuspid versus trileaflet aortic valves. J Surg Res 123 (2005) 40-48
30. Koullias G.J., Ravichandran P., Korkolis D.P., et al. Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections. Ann Thorac Surg 78 (2004) 2106-2110
31. Tamarina N.A., McMillan W.D., Shively V.P., et al. Expression of matrix metalloproteinase and their inhibitors in aneurysms and normal aorta. Surgery 122 (1997) 265-271
32. Hojo Y., Ikeda U., Ueno S., et al. Expression of matrix metalloproteinases in patients with acute myocardial infarction. Jpn Circ J 65 (2001) 71-75
33. Tziakas D.N., Chalikas G.K., Hatzinikollaou E.I., et al. N-terminal Pro-B-type natriuretic peptide and matrix metalloproteinases in early and late left ventricular remodeling after acute myocardial infarction. Am J Cardiol 96 (2005) 31-34
34. Rohde L.E., Ducharme A., Arroyo L.H., et al. Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99 (1999) 3063-3070